Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Dayer, Julie Anne ^a   Siegrist, Claire Anne ^a,b   Huttner, Angela ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; PLACEBO;

ADULT; AGED; ARTHRITIS; ARTICLE; DRUG MEGADOSE; EBOLA HEMORRHAGIC FEVER; FEMALE; HEALTH SURVEY; HIGH INCOME COUNTRY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; JOINT SWELLING; LOW DRUG DOSE; MALE; MEDICAL DOCUMENTATION; MIDDLE AGED; MOTIVATION; NORMAL HUMAN; PATIENT SATISFACTION; PERCEPTION; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL; SKIN DEFECT; VOLUNTEER; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; EBOLAVIRUS; FEEDBACK SYSTEM; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; OUTCOME ASSESSMENT; QUESTIONNAIRE; SELF REPORT; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGED; EBOLA VACCINES; EBOLAVIRUS; FEEDBACK; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PERCEPTION; SELF REPORT; SOCIOECONOMIC FACTORS; SURVEYS AND QUESTIONNAIRES; VOLUNTEERS; YOUNG ADULT;

EID: 85014841210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173148     Document Type: Article

References (9)

1. Chu SH, Jeong SH, Kim EJ, Park MS, Park K, Nam M, et al. The views of patients and healthy volunteers on participation in clinical trials: an exploratory survey study. Contemp Clin Trials. 2012; 33 (4):611-9. doi: 10.1016/j.cct.2012.02.018 PMID: 22405971
2. Casassus B. France releases interim report on drug trial disaster. Lancet. 2016; 387(10019):634-5. doi: 10.1016/S0140-6736(16)00318-4 PMID: 26876704
3. Attarwala H. TGN1412: From Discovery to Disaster. J Young Pharm. 2010; 2(3):332-6. doi: 10.4103/ 0975-1483.66810 PMID: 21042496
4. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016; 374(17):1647-60. doi: 10.1056/ NEJMoa1502924 PMID: 25830326
5. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebocontrolled phase 1/2 trial. The Lancet Infectious diseases. 2015; 15(10):1156-66. Epub 2015/08/08. doi: 10.1016/S1473-3099(15)00154-1 PMID: 26248510
6. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Munoz P, et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine-Preliminary Report. N Engl J Med. 2015. Epub 2015/04/02.
7. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015; 386(9996):857-66. doi: 10.1016/ S0140-6736(15)61117-5 PMID: 26248676
8. Nisbett RE, Wilson TD. The halo effect: Evidence for unconscious alteration of judgments. Journal of Personality and Social Psychology. 1977; 35(4): 250-6.
9. Report on Participation Experiences. https://www.ciscrip.org/download/2015-perceptions-insightsstudy-participant-experiences/?wpdmdl=5742